Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
BEIGENE SP ADS (NQ: BGNE)
192.98 USD  -0.50 (-0.26%)
Official Closing Price  /  Updated: 8:00 PM EDT, May 23, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 177,368
Open 195.51
Bid (Size) 190.00 (200)
Ask (Size) 195.99 (100)
Prev. Close 193.48
Today's Range 191.22 - 196.93
52wk Range 36.51 - 202.88
Shares Outstanding 53,760,296
Dividend Yield N/A
Performance
YTD
+91.43%
+91.43%
1 Month
+13.76%
+13.76%
3 Month
+28.72%
+28.72%
6 Month
+124.19%
+124.19%
1 Year
+424.12%
+424.12%
Top News
More News
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer
BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of... Read More
from GlobeNewswire News Releases
BeiGene to Present at the 2018 UBS Global Healthcare Conference
BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of... Read More
from GlobeNewswire News Releases
More News
Read More
BeiGene Reports First Quarter 2018 Financial Results
from GlobeNewswire News Releases
BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference
from GlobeNewswire News Releases
BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.
from GlobeNewswire News Releases
Technical Perspectives on Biotech Stocks -- Axovant Sciences, Aytu BioScience, BeiGene, and Bellicum Pharma
from PR Newswire
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting
from GlobeNewswire News Releases
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
from GlobeNewswire News Releases
Week in Review: Fosun in $2 Billion Bidding War for US Rights to Novartis' Generic Drugs
from ChinaBio® Today
These Stocks Have Quadrupled in Just 1 Year
category LGCY , Market News , BGNE , and 2 more.
from Motley Fool
BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients
from ChinaBio® Today
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial